Literature DB >> 87263

Potential for therapy of drugs and hyperthermia.

G M Hahn.   

Abstract

The interaction of hyperthermia (41--45 degrees C) and chemotherapeutic agents frequently results in increased cytotoxicity over that predicted for an additive effect, although to date only a very limited number of drugs have been examined for such a possible interaction. At 42 degrees C, the upper limit of temperature useful for whole-body hyperthermia, the most promising agents of those examined to date appear to be the nitrosoureas and cis-platinum. Insufficient data exist for cyclophosphamide, whose long plasma half-life makes it an attractive candidate. Localized heating seems optimum at higher temperatures (43--45 degrees C). At these temperatures, not only those drugs effective at 42 degrees C but particularly bleomycin and possibly amphotericin B become candidates. No data exist in the literature on possible "thermic sensitizers," i.e., drugs which are noncytotoxic at 37 degrees C but which become effective at elevated temperatures. Two special cases are Adriamycin and actinomycin D. These drugs may be contraindicated for clinical use, since not only synergism but also protection by hyperthermia have been demonstrated, depending upon the time-sequence relationships of the heat and drug treatments.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87263

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.

Authors:  Tristan D Yan; Christopher Qian Cao; Stine Munkholm-Larsen
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

2.  Does doxorubicin survive thermal ablation? Results of an ex vivo bench top study.

Authors:  Joseph D Morrison; Collin K Schlager; Amanda E Lee; Richard B van Breemen; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

3.  Influence of hyperthermia on efficacy and uptake of carbon nanohorn-cisplatin conjugates.

Authors:  Matthew R DeWitt; Allison M Pekkanen; John Robertson; Christopher G Rylander; Marissa Nichole Rylander
Journal:  J Biomech Eng       Date:  2014-02       Impact factor: 2.097

4.  Spatially controlled photothermal heating of bladder tissue through single-walled carbon nanohorns delivered with a fiberoptic microneedle device.

Authors:  R Lyle Hood; William F Carswell; Amanda Rodgers; Mehmet A Kosoglu; Marissa Nichole Rylander; David Grant; John L Robertson; Christopher G Rylander
Journal:  Lasers Med Sci       Date:  2012-10-04       Impact factor: 3.161

5.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

6.  Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Authors:  Laura E Strong; Shreyas N Dahotre; Jennifer L West
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

7.  [Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperthermia].

Authors:  E Biwer; M Lorenz; M Habs; D Schmähl
Journal:  Langenbecks Arch Chir       Date:  1984

8.  Metabolic changes in cimetidine treatment for scald injury on the peritoneo-serosal surface in far-advanced gastric cancer patients treated by intraperitoneal hyperthermic perfusion.

Authors:  S Fujimoto; M Takahashi; K Kobayashi; M Kokubun; R D Shrestha; S Kiuchi; C Konno
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Combined effect of pH and sodium cyanate on the inhibition of tumor cell proliferation and metabolism by BCNU and hyperthermia.

Authors:  J J Hu; K A Zirvi; M A Lea
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  [Effect of moderate local hyperthermia in combination with chemotherapy with cyclophosphamide or N-nitroso- 1,3-bis(2-chloroethyl)urea(BCNU) on Yoshida sarcoma implanted in the descending colon of rats. 1. Repeated hyperthermia within 8 days and combination of chemotherapy followed by hyperthermia 24 h later].

Authors:  M Lorenz; M Habs; D Schmähl
Journal:  Langenbecks Arch Chir       Date:  1983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.